Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Open-Label Single-Arm Study of Zilucoplan in Treatment-Naïve Paroxysmal Nocturnal Hemoglobinuria
2018-003956-19Phase 3Terminated
- Sponsor
- Ra Pharmaceuticals
- Start
- Jan 2019
- Modality
- Cyclic Peptides → Modified Peptides → Peptides
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of zilucoplan in paroxysmal nocturnal hemoglobinuria (PNH), sponsored by Ra Pharmaceuticals. Primary endpoint: Hemoglobin stabilization. Started Jan 2019; status: terminated.
02
Drugs
zilucoplan
03
Conditions
paroxysmal nocturnal hemoglobinuria (PNH)
Beyond the preview
Go deeper on 2018-003956-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-003956-19.